

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19372 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/565**,  
31/66, 9/08, A61P 35/00, A61K 47/18

(21) International Application Number: **PCT/EP00/08983**

(22) International Filing Date:  
13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9921960.2 16 September 1999 (16.09.1999) GB

(71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN S.P.A.** [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MUGGETTI**, Lorena [IT/IT]; Via Trento, 38, I-20036 Meda (IT). **COLOMBO**, Paolo [IT/IT]; Via Ludovico Cavaleri, 3, I-20147 Milan (IT). **MARTINI**, Alessandro [IT/IT]; Via Desiderio da Settignano, 14, I-20149 Milan (IT). **BUZZI**, Giovanni [IT/IT]; Via F. Poggi, 14, I-20131 Milan (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/19372 A1**

(54) Title: FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND AMINO ACIDS

(57) Abstract: A pharmaceutical formulations which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a basic amino acid. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables the estramustine phosphate to be administered with no side effects at the site of injection.

**FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE  
AND AMINO ACIDS**

5

The present invention relates to pharmaceutical formulations of estramustine phosphate for parenteral use and, more particularly, to formulations of estramustine phosphate for parenteral use further comprising basic amino acids.

10

Estramustine phosphate (The Merck Index, XII Ed., No. 3749, 1996) is an estradiol-17 $\beta$ -phosphate derivative widely known in the art as antitumor agent, currently used in the treatment of advanced adenocarcinoma of the prostate. The drug is usually administered orally, preferably at a dose of 10-15 mg/kg/day. Intravenous administration, however, is also adopted in some particular cases. For example, initial intravenous administration of estramustine phosphate, followed by oral administration, has been reported at dosages paralleling the oral administration for the drug, i.e. 300-600 mg daily given intravenously and usually repetitively over for several consecutive days (see, for a reference, British Journal of Urology, 1977, 49, 73-79; J. Urol. 108:303-306, 1972; Eur. Clin. Pharmacol. 26(1), 113-119, 1984; Eur. Urol. 1990, 17, 216-218).

20

25

Estramustine phosphate as well as other well-known cytotoxic compounds used in antitumor therapy are known to cause, or potentially cause, vascular damages at the site of injection when parenterally, in particular intravenously, administered.

30

As an example, studies in patients treated with estramustine phosphate administered as a slow intravenous injection or as a bolus, at 300 mg/day, revealed

35

thrombophlebitis and local irritations at the peripheral intravenous injection sites.

These drawbacks are considered major limitations for the intravenous administration of estramustine phosphate, thus requiring, in many patients, the establishment of central line administration or, in some cases, even discontinuation of the treatment.

With the aim of minimising the unwanted effects associated with the intravenous administration of cytotoxic agents, a few means are reported in the art.

Among them is the use of cyclodextrins, for instance hydroxypropyl-cyclodextrin, in the preparation of formulations for parenteral administration of cytotoxic known to cause ulcerative lesions. See, for a reference, US patent No. 5,804,568 in the name of Supergen Inc.

Also known in the art are formulations for the intravenous administration of estramustine phosphate containing human albumin, reported to be characterised by fewer local side-effects upon injection of the active (see, for a reference, H. Schutz et al.; Krankenhauspharmazie, II year, issue No. 3, 1988).

In this respect, we found formulations for parenteral use comprising estramustine phosphate together with a basic amino acid which, unexpectedly, resulted to achieve optimal protection from side-effects associated with estramustine administration.

It is therefore the object of the present invention a formulation for parenteral use comprising estramustine phosphate and a basic amino acid.

Once administered intravenously to patients, the formulations object of the present invention do not provoke ulcerative damages, nor thrombophlebitis, at the site of injection.

In the present description, with the term basic amino acid we preferably intend a basic  $\alpha$ -amino acid; preferred basic amino acids are selected from the group consisting of arginine, histidine and lysine.

5 Even more preferably, the formulations object of the present invention comprise arginine.

With the term formulation comprising estramustine phosphate we intend any formulation of estramustine phosphate, as the active ingredient, either in the acid form or as a  
10 pharmaceutically acceptable salt for parenteral use such as, for instance, the salts of estramustine phosphate with basic amino acids themselves or with N-methyl glucamine, otherwise referred to as meglumine.

Preferably, the formulations of the invention comprise  
15 estramustine phosphate in the form of its arginine or meglumine salt.

From the foregoing, it is clear to the man skilled in the art that the formulations of the present invention may  
20 contain the basic amino acid, either in the form of its salt with estramustine phosphate as well as in admixture with an estramustine phosphate salt for parenteral use.

According to a preferred embodiment of the invention, it is  
25 herewith provided a formulation for parenteral use comprising estramustine phosphate, in the form of its arginine salt, optionally in admixture with additional amounts of a basic amino acid, e.g. arginine.

30 Another preferred embodiment of the invention is a formulation for parenteral use comprising estramustine phosphate, in the form of its meglumine salt, in admixture with arginine.

35 In another preferred embodiment, estramustine phosphate is provided in lyophilised form and the basic amino acid is

provided in physiological solution. Formulations of this type may typically be provided as a kit.

The formulations object of the present invention may  
5 further contain additional excipients for parenteral use.  
Among them are also those excipients known in the art to  
reduce the side effects associated with the parenteral  
administration of cytotoxic agents (herewith referred to as  
protective agents) such as, for instance, human albumin,  
10 cyclodextrins, sulfoalkyl ether cyclodextrins and  
derivatives thereof.  
Preferably, the formulations of the invention additionally  
comprise human albumin.

15 Very interestingly, the formulations of the invention also  
containing a given amount of human albumin are unexpectedly  
less toxic than the corresponding estramustine phosphate  
formulations containing the same amount of human albumin,  
as the sole protective agent against ulcerative damages and  
20 thrombophlebitis at the site of injection.

It is therefore a further object of the invention a  
formulation for parenteral use comprising estramustine  
phosphate and a basic amino acid in admixture with human  
25 albumin.

All of the above formulations are preferably intended for  
intravenous use. As such, they can be administered to  
patients either as a slow injection, e.g. over about 30  
30 minutes to about 3 hours, or as a bolus injection, also  
referred to as IV (intravenous) push.

In addition, the formulations of the invention provide a  
very advantageous method for delivering estramustine  
35 phosphate intravenously, even when high doses of the active  
are needed.

It is therefore a further object of the invention a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 1300 mg, and a basic amino acid.

- 5 According to another preferred embodiment of the invention, it is further provided a formulation for parenteral use comprising estramustine phosphate, as a single infusion dosage of the active exceeding 950 mg/m<sup>2</sup>, and a basic amino acid.

10

The formulations of the invention allow the administration of the active either as a single agent or, alternatively, according to a combined chemotherapy regimen.

- As an example, the above formulations can be administered  
15 in combination with one or more chemotherapeutic agents such as, for instance, taxane derivatives, e.g. paclitaxel and docetaxel; camptothecin and derivatives thereof, e.g. CPT-11, 9-amino-camptothecin; anthracycline derivatives, e.g. doxorubicin, epirubicin, idarubicin, daunorubicin,  
20 alkylcycline (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); etoposide; navelbine; vinblastine; platinum derivatives, e.g. carboplatin and cisplatin; angiogenesis inhibitors, e.g. Sugen SU-5416 and Sugen SU-6668; and the like,  
25 optionally within liposomal formulations thereof.

- Therefore, it is a further object of the present invention a product containing a formulation for parenteral use comprising estramustine phosphate and a basic amino acid,  
30 preferably arginine, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

#### Toxicology

- 35 To study the local irritant effects of estramustine phosphate (hereinafter referred to as EMP) after repeated intravenous administrations to rats, the active was

prepared, according to the present invention, either in the form of a salt with a basic amino acid and/or in admixture with a basic amino acid. Subsequently, the said preparations were dissolved in different vehicles such as water solution for injection and water solution for injection further containing human albumin (hereinafter referred to as HA). In addition, formulations of estramustine phosphate in the form of meglumine (hereinafter referred to as MEG) salts, optionally in admixture with HA only, were used for comparison. In particular, the following water for injection solutions (Table I) wherein either the active EMP as well as the basic amino acid or HA are expressed in terms of molar or weight ratios, were prepared and tested:

Table I

| Solution                                | Molar ratio<br>(mol/mol) | Weight ratio<br>(w/w) |
|---|--------------------------|-----------------------|
| a)negative control<br>water for inject. | -                        | -                     |
| b)positive control<br>EMP-MEG salt      | EMP:MEG=1:1              | -                     |
| c)comparison<br>EMP-MEG salt + HA       | EMP:MEG=1:1              | EMP:HA=1:0.21         |
| d)<br>EMP-Arg salt                      | EMP:Arg=1:1              |                       |
| e)<br>EMP-Arg salt + Arg                | EMP:Arg=1:2              |                       |
| f)<br>EMP-Arg salt + HA                 | EMP:Arg=1:1              | EMP:HA=1:0.21         |
| g)<br>EMP-MEG salt + Arg                | EMP:MEG:Arg=1:1:2        |                       |

Male Sprague-Dawley rats were used because of their acceptance as a predictor of toxic change in man. The rats were 6 weeks old at the start of the study.

The above formulations were administered to groups of rats as a repeated intravenous injection during 3 days. Rats were then sacrificed: a half of the rats at the fourth day and a half at the fifth day.

- 5 The dose level of estramustine phosphate, in all the different tested solutions, was of 150 mg/kg/day. Clinical observations were recorded daily. Thrombophlebitic side effects resulted in a dark bluish/blackish coloration of the tail during the treatment period.
- 10 A score system based on tail coloration and its extension was used to evaluate the different tested formulations. The score system considered the formulation of estramustine phosphate salt with meglumine, solution (b), as the positive control (i.e. marked toxicity). Water for
- 15 injection (a) was administered to the control group as negative control (i.e. no toxicity signs). Histological evaluation was carried out on the tail of the rats treated with the composition of the invention. Estramustine phosphate in a water solution (b) induced, at
- 20 the used dose, local irritant effects at the injection site after the first administration and marked toxicity signs at the end of the experiment. Likewise, toxicity signs at the injection site were also observed for the comparison (c) EMP solution containing
- 25 human albumin, as the sole protective excipient against ulcerative damages at the injection site. On the contrary, a markedly reduced toxicity or even no toxicity was observed with the formulations of the invention containing arginine (d), (e) and (g), optionally
- 30 in admixture with human albumin (f). The histological evaluation of the tail of the rats treated with these formulations confirmed the above findings. In addition, the protective effect exerted by the basic amino acid, according to the invention, can clearly be
- 35 evidenced by considering the formulation (f) in comparison to the formulations (c) for which toxicity signs were observed. Very interestingly, in fact, both formulations



contained the same amount of human albumin with respect to the active.

It was thus concluded that estramustine phosphate in a water solution containing a basic amino acid, either in the form of a salt with estramustine phosphate or in admixture with the same, induced markedly less local irritant effects when compared with a water solution of estramustine phosphate itself.

Even more surprisingly, the formulations of the invention produced less local irritant effects also in comparison to analogous solutions of estramustine phosphate containing known protective excipients, for instance human albumin.

One particularly preferred schedule for administering the formulation of estramustine phosphate according to the invention is a single infusion given once weekly to a maximal dose of 4000 mg or 3500 mg/m<sup>2</sup>.

Another preferred schedule is the administration of a single drug infusion once every two to four weeks.

One schedule may be preferred over another in consideration of schedules with other optional concomitant therapy. These schedules may repeat in serial or as repetitive fashion.

The formulations of the present invention are useful in antitumor therapy, particularly in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer and cancers of the brain.

30

In addition to the above, we also noticed that arginine and the pharmaceutically acceptable salts thereof for parenteral use, exerted their protective effects against the occurrence of thrombophlebitis also when used in combination with several other antineoplastic agents known to cause, or potentially cause, ulcerative damages at the site of injection, when administered intravenously.

It is therefore a further object of the invention a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, an antineoplastic agent known to cause ulcerative damages at the site of injection upon intravenous administration, and arginine or a pharmaceutically acceptable salt thereof.

Besides estramustine phosphate, other antineoplastic agents are known to cause, at least potentially, ulcerative damages and thrombophlebitis at the site of injection. Preferably, these antineoplastic agents according to the invention are selected from the group consisting of anthracycline derivatives such as doxorubicin, epirubicin, idarubicin, daunorubicin and alkycycline (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); and angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668.

From the foregoing, it is a further object of the invention the use of arginine, or pharmaceutically acceptable salts thereof, in the preparation of a medicament for the treatment and prevention of side-effects associated with the intravenous administration of antineoplastic agents:

As set forth above, these side-effects comprise ulcerative lesions and thrombophlebitis at the site of injection.

In the present description, unless otherwise specified, with the term pharmaceutically acceptable salt of arginine, we intend any salt for parenteral use including, preferably, the arginine addition salt with hydrochloric, glutamic or aspartic acid.

The formulations object of the present invention are prepared according to conventional techniques adopted in the preparation of pharmaceutical forms for parenteral use.

Typically, a proper amount of estramustine phosphate is dispersed in water and then dissolved by adding at least an equimolar amount of a basic amino acid, for instance arginine.

- 5 A further amount of the given amino acid, e.g. arginine, can be present in order to reach an estramustine phosphate:arginine molar ratio higher than 1:1, respectively.

- Alternatively, a proper amount of estramustine phosphate in  
10 the form of a pharmaceutically acceptable salt for parenteral use, e.g. estramustine phosphate meglumine salt, either as a dry powder or into a lyophilised form, is dissolved in a pharmaceutically acceptable solution for parenteral use, for instance sterile water or aqueous  
15 dextrose solution, e.g. 5% dextrose in water for intravenous administration, and then admixed with a proper amount of a basic amino acid, for instance arginine.

- The above admixture is then stirred, sterilised, and subsequently lyophilised according to conventional  
20 techniques.

- The freeze-dried formulation is prepared and stored in vials for injection; the addition of a proper amount of sterile water or a physiological solution for parenteral use enables the preparation of the final formulation to be  
25 injected.

- The above method is also suitable for preparing high dosages estramustine phosphate formulations whilst maintaining the desired weight or molar ratio between the  
30 components.

The unit strength of the formulation to be injected depended on the concentration of the active in the solution itself and, of course, on the filling volume of the vials used to prepare the final formulation.

35

Additionally, besides the aforementioned human albumin, cyclodextrins, sulfoalkyl ether cyclodextrins and

derivatives thereof, the formulations of the invention may optionally contain additional pharmaceutically acceptable excipients for parenteral administration such as, for instance, bulking agents, e.g. lactose or mannitol, pH buffering agents, anti-oxidant agents, preservative agents, tonicity adjusters and the like.

From the foregoing, it is clear to the man skilled in the art that the above methods for preparing the estramustine formulations apply as well to arginine-containing formulations comprising antineoplastic agents other than estramustine phosphate, and known to cause, or potentially cause, thrombophlebitic side-effects upon intravenous administration.

The following examples are herewith intended to better illustrate the present invention without representing any limitation to it.

20

#### Example 1

Preparation of estramustine phosphate N-methyl glucamine salt in admixture with human albumin (estramustine phosphate:meglumine=1:1 molar ratio, estramustine phosphate:albumin=1:0.21 weight ratio)

300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 120.8 mg of N-methyl-glucamine were then added under stirring to the watery dispersion of the active and, after a few minutes, a clear solution was obtained. 0.250 ml of a commercially available solution of human albumin at 25% concentration were added whilst maintaining the solution under stirring.

The obtained solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 6.25 mg/ml of human albumin (1:0.21 weight ratio respectively).

A solution prepared as previously described, properly sterilised by filtration, was tested for its local vein tolerability in rats.

5

**Example 2**

The formulation described in Example 1 was also prepared by dissolving the commercially available Estracyt® freeze-dried formulation containing 300 mg/vial of the active. The reconstitution of the formulation was made by using 10 ml  
10 of a 6.25 mg/ml human albumin solution so as to obtain a final concentration of 30 mg/ml of estramustine phosphate and 6.25 mg/ml of human albumin (1:0.21 weight ratio respectively).

The albumin solution could be prepared either by dissolving  
15 in water a proper amount of human albumin as a dry powder or by properly diluting a commercially available human albumin solution.

**Example 3**

20 **Preparation of estramustine phosphate arginine salt  
(estramustine phosphate:arginine=1:1 molar ratio)**

300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 101 mg of arginine base were then added to the  
25 watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained.

The prepared solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 10.1 mg/ml of  
30 arginine (1:1 molar ratio respectively).

A solution prepared as previously described, properly sterilised by filtration, was tested for its local vein tolerability in rats.

**Example 4**

**Preparation of estramustine phosphate arginine salt in admixture with arginine (estramustine phosphate:arginine=1:2 molar ratio)**

5 300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 202 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained. The basic pH  
10 of the obtained solution was brought to the physiological value of about 7.5 by slow addition of diluted hydrochloric acid.

The solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml  
15 of estramustine phosphate and 20.2 mg/ml of arginine (1:2 molar ratio respectively).

A solution prepared as previously described, properly sterilised by filtration, was tested for its local vein tolerability in rats.

20

**Example 5**

**Preparation of estramustine phosphate arginine salt in admixture with human albumin (estramustine phosphate:arginine=1:1 molar ratio, estramustine  
25 phosphate:albumin=1:0.21 weight ratio)**

300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 101 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under  
30 stirring until a clear solution was obtained. 0.250 ml of a commercially available solution of human albumin at 25% concentration were added, maintaining the solution under stirring.

The solution was then brought to the final volume of 10 ml  
35 with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate, 10.1 mg/ml of arginine and 6.25 mg/ml of human albumin. The molar and weight ratios between

the components of the solution were as follows:  
estramustine phosphate:arginine 1:1 molar ratio,  
estramustine phosphate:human albumin 1:0.21 weight ratio.  
A solution prepared as previously described, properly  
5 sterilised by filtration, was tested for its local vein  
tolerability in rats.

#### Example 6

Preparation of estramustine phosphate N-methyl glucamine  
10 salt in admixture with arginine (estramustine  
phosphate:meglumine:arginine=1:1:2 molar ratio)  
300 mg of estramustine phosphate were weighed in a beaker  
and dispersed by means of magnetic stirring in 5 ml of  
water. 120.8 mg of N-methyl-glucamine were then added under  
15 stirring to the watery dispersion of the active and, after  
a few minutes, a clear solution was obtained. A total  
amount of 202 mg of arginine was then added to the above  
described solution by using a suitable mixture of arginine  
base and hydrochloride, in order to maintain the pH around  
20 the physiological value of 7.5.  
The solution was then brought to the final volume of 10 ml  
with water so as to reach a final concentration of 30 mg/ml  
of estramustine phosphate and 20.2 mg/ml of arginine (1:2  
molar ratio respectively).  
25 A solution prepared as previously described, properly  
sterilised by filtration, was tested for its local vein  
tolerability in rats.

#### Example 7

30 The formulation described in Example 6 was also prepared by  
solubilization of the commercially available Estracyt®  
freeze-dried formulation containing 300 mg/vial of the  
active. The reconstitution of the formulation was made by  
using 10 ml of a 20.2 mg/ml arginine solution so as to  
35 reach a final concentration of 30 mg/ml of estramustine  
phosphate and 20.2 mg/ml of arginine (1:2 molar ratio  
respectively).

The arginine solution used to dissolve the freeze-dried formulation contained a proper mixture of arginine base and hydrochloride, in order to maintain the pH around the physiological value of 7.5.

5

#### Example 8

**Preparation of a formulation comprising doxorubicin and arginine in a 1:1 molar ratio.**

Doxorubicin hydrochloride (40 mg) and arginine (12 mg) were weighed in a flask and the admixture was dissolved in a physiological solution (15 ml) of NaCl 0.9% w/v, under stirring. A solution of hydrochloric acid was then added up to pH = 3. The solution thus prepared was then diluted with the above physiological solution up to a final volume of 20 ml so as to reach a final concentration of 2 mg/ml of doxorubicin and 0.6 mg/ml of arginine (molar ratio 1:1, respectively).

#### Example 9

**Preparation of a formulation comprising doxorubicin and arginine in a 1:2 molar ratio**

By working as above described in example 8 and by using an amount of arginine as twice, that is 24 mg of arginine per 40 mg of doxorubicin hydrochloride, a solution comprising doxorubicin and arginine in a molar ratio 1:2, respectively, was thus prepared.

#### Example 10

**Preparation of a formulation comprising Sugan SU-5416 and arginine in a 1:1 molar ratio**

10 ml of an aqueous solution of NaCl (0.9% w/v) were diluted with 10 ml of water in a flask so as to obtain a solution of NaCl at 0.45% w/v.

Arginine hydrochloride (39.79 mg) was then added to the resultant solution and dissolved by shaking.

The solution thus prepared was used to dilute a solution of Sugan SU-5416 having the following composition:



| Component         | Amount % (w/v) in the formulation |
|-------------------|-----------------------------------|
| Sugen SU 5416     | 0.45 %                            |
| PEG 400           | 45 %                              |
| Benzyl alcohol    | 2 %                               |
| Cremophor EL      | 31.5 %                            |
| Anhydrous Ethanol | Up to 100                         |

The dilution was carried out by admixing one part of the formulation containing the active Sugén SU-5416 with two parts of the solution containing arginine, so as to obtain a final solution of Sugén SU-5416 and arginine in a molar ratio 1:1.

#### Example 11

#### 10 Preparation of a formulation comprising Sugén SU-5416 and arginine in a 1:2 molar ratio

By working as above described in example 10 and by using an amount of arginine hydrochloride as twice, that is 79.58 mg, a solution comprising Sugén SU-5416 and arginine in a 15 1:2 molar ratio, respectively, was thus prepared.

## CLAIMS

1. A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a basic amino acid.  
5
2. A formulation according to claim 1 wherein the basic amino acid is arginine.
- 10 3. A formulation according to claim 1 or 2 wherein estramustine phosphate is in the form of a pharmaceutically acceptable salt for parenteral use.
- 15 4. A formulation according to claim 3 wherein the estramustine phosphate is in the form of a salt with arginine, histidine, lysine or N-methyl glucamine.
- 20 5. A formulation according to claim 4 wherein the estramustine phosphate is in the form of a salt with arginine or N-methyl glucamine.
- 25 6. A formulation according to anyone of the preceding claims comprising estramustine phosphate and arginine in a molar ratio lower than 1:1.
7. A formulation according to claim 6 comprising estramustine phosphate and arginine in a molar ratio of about 1:2.
- 30 8. A formulation according to claim 1 which further comprises human albumin, a cyclodextrin or a sulfoalkyl ether cyclodextrin.
- 35 9. A formulation according to claim 1 which further comprises human albumin.

10. A formulation according to any one of the preceding claims which is in single infusion dosage form comprising at least 1300 mg of the estramustine phosphate.
- 5 11. A formulation according to any one of the preceding claims which is in single infusion dosage form comprising at least 950 mg/m<sup>2</sup> of the estramustine phosphate.
- 10 12. A formulation according to claim 10 or 11 wherein the basic amino acid is arginine.
13. A formulation according to any one of the preceding claims for intravenous use.
- 15 14. A formulation according to any one of the preceding claims for use in the treatment of cancer.
15. A formulation as claimed in claim 14 wherein the cancer is prostate cancer, breast cancer, melanoma, lung  
20 cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.
16. A formulation according to claim 1 wherein the parenterally acceptable carrier is a physiological solution  
25 for parenteral use which contains the basic amino acid, and the estramustine phosphate is in lyophilised form.
17. A product which comprises:
- 30 (i) a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a basic amino acid, and  
(ii) one or more chemotherapeutic agents,  
as a combined preparation for simultaneous, separate or  
sequential use in anticancer therapy.
- 35 18. A product according to claim 17 wherein the basic amino acid is arginine.

19. A product according to claim 17 or 18 wherein the chemotherapeutic agent is selected from the group consisting of taxane derivatives such as paclitaxel and docetaxel; camptothecin and derivatives thereof such as CPT-11 and 9-amino-camptothecin; anthracycline derivatives such as doxorubicin, epirubicin, idarubicin, daunorubicin, alkycycline (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); etoposide; navelbine; vinblastine; platinum derivatives such as carboplatin and cisplatin; angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668; optionally within liposomal formulations thereof.
20. A product according to claim 17 for intravenous use.
21. A product according to claim 17 for use in the treatment of prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.
22. A formulation as defined in claim 13 for use in suppressing or reducing the side-effects associated with the intravenous administration of estramustine phosphate and pharmaceutically acceptable salts thereof.
23. A formulation according to claim 22 wherein the side effects comprise ulcerative lesions and thrombophlebitis at the site of injection.
24. A product which comprises estramustine phosphate in lyophilised form and a physiological solution for parenteral use containing a basic amino acid.
25. Use, in the manufacture of a medicament for parenteral administration, of estramustine phosphate and a basic amino acid.

26. Use according to claim 25 wherein the medicament is for intravenous administration.

27. A pharmaceutical formulation which comprises a  
5 parenterally acceptable carrier or diluent, an antineoplastic agent known to cause ulcerative damages at the site of injection upon intravenous administration, and arginine or a pharmaceutically acceptable salt thereof.

10 28. A formulation according to claim 27 wherein the antineoplastic agent is selected from the group consisting of anthracycline derivatives such as doxorubicin, epirubicin, idarubicin, daunorubicin and alkycycline (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-  
15 daunorubicin; internal code PNU 159548); and angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668.

29. Use of arginine, or of pharmaceutically acceptable salts thereof, in the preparation of a medicament for the  
20 treatment and prevention of side-effects associated with the intravenous administration of antineoplastic agents.

30. Use according to claim 29 wherein the side-effects comprise ulcerative lesions and thrombophlebitis at the  
25 site of injection.

31. Use according to claim 29 wherein the antineoplastic agent is selected from the group consisting of estramustine phosphate; anthracycline derivatives such as doxorubicin,  
30 epirubicin, idarubicin, daunorubicin and alkycycline (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyl-daunorubicin; internal code PNU 159548); and angiogenesis inhibitors such as Sugen SU-5416 and Sugen SU-6668.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/08983

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/565 A61K31/66 A61K9/08 A61P35/00 A61K47/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | US 5 785 976 A (K.WESTESEN ET AL.)<br>28 July 1998 (1998-07-28)<br>claims 1,4,5,8-11,14,15,17,18,20<br>column 15, line 15 - line 17<br>column 15, line 32 - line 33                     | 1,8,9,<br>13,25,26    |
| E          | WO 00 59475 A (LIPOCINE INC., U.S.A.)<br>12 October 2000 (2000-10-12)<br>claims<br>1-4,8,19,48-50,57-59,61,63,65,67-78,85-90<br>claims 110,112-115<br>page 13, line 24 - line 27<br>-/- | 1,8,13,<br>25,26      |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

19 January 2001

Date of mailing of the international search report

29/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/EP 00/08983

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|--|--|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| A  | <p>US 5 807 572 A (S. KIM ET AL.)<br/>15 September 1998 (1998-09-15)<br/>claims 1,3,25-39<br/>column 5, line 39 - line 41<br/>column 6, line 58 - column 7, line 3<br/>column 7, line 41<br/>column 7, line 60 - line 67<br/>table 1</p> | 27-31                 |
| A  | <p>EP 0 612 530 A (SNOW BRAND MILK PRODUCTS<br/>CO. LTD.,JP) 31 August 1994 (1994-08-31)<br/>claims 1-4<br/>table 4</p>  | 27-31                 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08983

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)   | Publication<br>date  |
|---|---------------------|--|--|
| US 5785976 A                              | 28-07-1998          | CA 2091152 A<br>US 5885486 A<br>AU 676279 B<br>AU 6225394 A<br>EP 0687172 A<br>FI 954143 A<br>JP 8507515 T<br>NO 953461 A<br>NZ 262541 A<br>WO 9420072 A | 06-09-1994<br>23-03-1999<br>06-03-1997<br>26-09-1994<br>20-12-1995<br>19-10-1995<br>13-08-1996<br>06-11-1995<br>24-04-1997<br>15-09-1994 |
| WO 0059475 A                              | 12-10-2000          | NONE   |  |
| US 5807572 A                              | 15-09-1998          | US 6071534 A<br>US 5723147 A   | 06-06-2000<br>03-03-1998   |
| EP 612530 A                               | 31-08-1994          | JP 6247872 A<br>AT 197404 T<br>AU 678421 B<br>AU 5630794 A<br>CA 2116192 A<br>DE 69426244 D<br>US 5510327 A<br>ZA 9401198 A                              | 06-09-1994<br>11-11-2000<br>29-05-1997<br>01-09-1994<br>24-08-1994<br>14-12-2000<br>23-04-1996<br>20-09-1994                             |